Correction: Programmable RNA microstructures for coordinated delivery of siRNAs.

J. M. Stewart,Mathias Viard,Hari K. K. Subramanian,B. Roark,K. Afonin,Elisa Franco

DOI: https://doi.org/10.1039/c7nr90063e

IF: 6.7

2017-04-13

Nanoscale

Abstract:Correction for 'Programmable RNA microstructures for coordinated delivery of siRNAs' by Jaimie Marie Stewart et al., Nanoscale, 2016, 8, 17542-17550.

What problem does this paper attempt to address?

Three-Dimensional Electrohydrodynamic Printing and Spinning of Flexible Composite Structures for Oral Multidrug Forms

Shuting Wu,Jing-Song Li,John Mai,Ming-Wei Chang

DOI: https://doi.org/10.1021/acsami.8b08880

IF: 9.5

2018-01-01

ACS Applied Materials & Interfaces

Abstract:A simple method to rapidly customize and to also mass produce oral dosage forms is arguably a current bottleneck in the development of modern personalized medicine. Specifically, delayed-release mechanisms with well-controlled dosage profiles for combinations of traditional Chinese herbal extracts and Western medications are not well established. Herein, we demonstrate a novel multidrug-loaded membrane sandwich with structures infused with ibuprofen (IBU) and Ganoderma lucidum polysaccharide (GLP) using three-dimensional electrohydrodynamic printing and electrospinning techniques. The resulting flexible membrane consists of microscaled, multilayered cellulose acetate (CA) membranes loaded with IBU in the shape of either concentric squares or circles, as the top and bottom layers of a sandwich structure. In between the CA-IBU layers are randomly electrospun polyvinyl pyrrolidone (PVP) layers loaded with GLP. The complete fibrous membrane sandwich can be folded and embedded into a 0-size capsule to achieve oral compliance. Simulated in vitro testing of gastric and intestinal fluids demonstrated a triphasic release profile. There was an immediate release of GLP after gastric juices dissolved the capsule shell and the PVP, followed by the short-term release of 60% of the IBU within an hour afterward, and the remaining IBU was released in a sustained manner following a Fickian diffusion profile. In summary, this multidrug (both hydrophilic and/or hydrophobic) oral system with precision-designed structures should enable personalized therapeutic dosing.
Preparation and Quality Control of Levamlodipine Besylate Orally Disintegrating Tablets

MA Li,WANG Cong-pin,ZHU Xing-guang,SHENG Xiao-ying

DOI: https://doi.org/10.3969/j.issn.1001-8255.2009.07.008

2009-01-01

Abstract:The orally disintegrating tablets of micronized levamlodipine besylate were prepared by direct powder compression with lactose and mannitol as fillers and polyplasdone as disintegrant. The formulation was optimized by orthogonal design. The uniformity of dosage units was good. The mean disintegrating time of the tablets in vitro and in oral cavity of six volunteers were both within 30 s. The in vitro dissolution of the tablets was above 90% in 5 min.
Study on pramipexole dihydrochloride sustained-release tablets

Rong SHENG,Zhi-guo WANG,Ning LI,Han-lin FENG

DOI: https://doi.org/10.3969/j.issn.1006-8783.2012.02.004

2012-01-01

Abstract:Objective To prepare sustained-release formulation of pramipexole dihydrochloride and study its in vitro release behaviors.Methods Pramipexole dihydrochloride sustained-release tablets were prepared with Hypromellose(HPMC) as matrix material,and Ethylcellulose(EC) as blockers.Technological parameters of tablets were screened with the accumulative releasing rate in vitro as index.Results In the optimal formulation,0.214% of pramipexole dihydrochloride,37.0% of HPMC K100M,38.0% of EC,23.0% of Pre-starch,1.00% of aerosil and 0.786% of magnesium stearate were selected as the main excipients.The release ratio of the optimal formulation was up to 90% in 24 hours and the pH value of release medium had no significant effects on the release of pramipexole dihydrochloride sustained-release tablets.The formulation demonstrated a typical extended release profile in the in vitro test.Conclusion The formulation had a good profile of extended releasing.The preparation process is simple,which is worth further development and application in the clinic.
Development and characterization of gastro-floating sustained-release capsule with improved bioavailability of levodopa

Hao Yuan,Zhengyu Zhang,Liandong Hu

DOI: https://doi.org/10.1007/s13346-022-01188-5

2022-06-06

Drug Delivery and Translational Research

Abstract:In this study, a new gastro-floating sustained-release capsule (GFC) with levodopa (LD) and benserazide hydrochloride (BH) was successfully developed. GFCs were prepared by filling the LD and BH granules into hard capsules and coated with cellulose acetate (CA) solution as a controlled-release layer. The effects of formulation factors on the release of GFCs were conducted. The AUC 0~24 (μg h/mL) of LD were 69.31 ± 3.61 (μg h/mL) and 28.87 ± 2.58 (μg h/mL) and the C max were 7.84 ± 0.34 (μg/mL) and 9.21 ± 1.04 (μg/mL) in the GFCs and commercial tablets respectively. The relative bioavailability of LD was 267.55 ± 34.54%. Compared with commercial tablets, the pharmacokinetic study indicated that the developed GFCs provided a better sustained-release effect and higher bioavailability than commercial tablets.

pharmacology & pharmacy,medicine, research & experimental
Novel liposomal formulations for protection and delivery of levodopa: Structure-properties correlation

Elena Allegritti,Sara Battista,Maria Anna Maggi,Claudia Marconi,Luciano Galantini,Luisa Giansanti

DOI: https://doi.org/10.1016/j.ijpharm.2023.123230

2023-08-25

Abstract:Liposomes are promising drug carriers for a wide range of central nervous system disorders, such as Parkinson's disease (PD), since they can protect active substances from degradation and could be administered intranasally, ensuring a direct access to the brain. Levodopa (LD), the drug commonly used to treat PD, spontaneously oxidizes in aqueous solutions and thus needs to be stabilized. Our investigation focuses on the preparation and the physico-chemical characterization of mixed liposomes to vehiculate LD and two natural substances (L-ascorbic acid and quercetin) that can prevent its oxidation and contribute to the treatment of Parkinson's disease. These co-loaded vesicles were prepared using a saturated phospholipid and structurally related cationic or analogue N-oxide surfactants and showed different properties, based on their composition. In particular, ex-vivo permeability tests using porcine nasal mucosa were performed, denoting that subtle variations of the lipids structure can significantly affect the delivery of LD to the target site.
Preparation and in vitro evaluation of a novel combined multiparticulate delayed-onset sustained-release formulation of diltiazem hydrochloride

Shengjun Chen,Jiabi Zhu,Ji Cheng

Pharmazie

Abstract:A combined delivery system, containing two kinds of diltiazem hydrochloride multi-layer coated pellets with different release characteristics, was developed to meet chronotherapeutic requirements. The dissolution studies in vitro indicated that the combined system could constantly release drug at a predetermined time in synchrony with the biologic rhythm of disease activity. These two kinds of pellets were mixed at the ratio 1:1. Pellet 2 could provide drug during the later phase of drug release from pellet 1, because the amount released was insufficient in the later phase (about 14-24 h after administration) for pellet 1. Addition of Tween 20 in the HPMC swelling layer was able to modify the hydration rate of HPMC layer which controlled the delayed time of the release system. It was found that the drug release kinetics followed Hixson-Crowell equation and this indicated that the main drug-transport mechanism inside the pellets was an erosion mechanism. The drug release rate was independent of the hydrodynamic conditions and pH of the external environment, and showed a decrease with increasing of osmotic pressure of the dissolution medium. These release characteristics indicated that the drug release from this system was driven by osmotic-pressure gradient.
Development of protocatechualdehyde proliposomes-based sustained-release pellets with improved bioavailability and desired pharmacokinetic behavior for angina chronotherapy

Shuangshuang Zhang,Hongxiang Yan,Panpan Yu,Yulong Xia,Wenli Zhang,Jianping Liu

DOI: https://doi.org/10.1016/j.ejps.2016.08.040

2016-10-10

Abstract:The present study was aimed to develope a proliposomal formulation to decrease the hepatic first-pass metabolism of protocatechualdehyde (PD), followed by pellet coating to modify the drug release for angina chronotherapy. PD proliposomes were prepared by depositing PD-phospholipid complex on mannitol powders to improve the drug encapsulation. Afterwards, the PD proliposomes were prepared into pellet cores via extrusion-spheronization using 10% κ-carrageenan as pelletization aid prior to the development of PD sustained-release pellets (PD-SRPs). Eudragit® NE 30D was chosen as coating material and the desired drug release profile of PD-SRPs was calculated for formulation optimization by deconvolution based on the circadian rhythm of variant angina. A high similarity factor (f2=85.72) was achieved when the coating weight was 30% and the sustained release behavior also prevented the destruction of liposomes by gastric fluids. Pharmacokinetic studies revealed a basically consistent trend between the actual and the predicted plasma concentration-time curve with absolute percent errors (%PE) of concentrations <10% in 2-12h. Meanwhile, a relative bioavailability of 200% was achieved compared with pure PD. Therefore, the development of proliposomes-based PD-SRPs was an effective strategy to provide both improved oral bioavailability and desired drug plasma concentration-time course for angina chronotherapy.
Testing HIV positive in pregnancy: A phenomenological study of women's experiences.

Andrew Lingen-Stallard,C. Furber,T. Lavender

DOI: https://doi.org/10.1016/j.midw.2016.02.008

IF: 2.64

2016-04-01

Midwifery

Abstract:
Non-invasive, continuous oral delivery of solid levodopa-carbidopa for management of Parkinson's disease

William L. Murch,John Spiridigliozzi,Adam Heller,Ephraim Heller

DOI: https://doi.org/10.1038/s41598-024-78145-4

IF: 4.6

2024-11-07

Scientific Reports

Abstract:When short plasma half-life drugs act only briefly, they require frequent or continuous administration. We report the engineering of a non-invasive oral drug delivery system for long-term, continuous administration of these drugs. Their non-invasive, long-term, continuous administration at daily doses exceeding 100 mg has, for many years, been considered an insurmountable challenge. We show that over 1200 mg/day of 4:1 levodopa-carbidopa (LD-CD) can be non-invasively and continuously extruded when formulated as a semisolid paste, loaded with 63%w/w of the solid drugs. The drug delivery system comprises a reusable orthodontic retainer with a co-molded pocket into which the patient inserts after each meal a new 1 mL propellant-driven, prefilled, disposable, drug delivery extruder. The paste is delivered to the lingual side of the teeth where it is mixed with saliva and swallowed. As reported elsewhere, a 15-day, 16 patient open label clinical trial of the drug delivery system continuously extruding LD-CD paste significantly reduces the variability of the plasma LD concentration and alleviates symptoms of advanced Parkinson's disease (PD) as compared to LD-CD tablets.

multidisciplinary sciences
Co-loading of Levodopa and Curcumin Using Brain-targeted Protocells for Improving the Efficacy of Parkinson's Disease

Wenkai Zhou,Chang Liu,Feifei Yu,Xia Niu,Xiaomei Wang,Guiling Li,Xinru Li

DOI: https://doi.org/10.21203/rs.3.rs-131164/v1

2021-01-01

Abstract:Abstract Parkinson's disease (PD), one of the most common movement and neurodegenerative disorders, is challenging to treat. Levodopa is a common clinical drug for controlling the symptoms of PD, but it only replenishes the missing dopamine, can’t protect dopaminergic neurons. While curcumin as a neuroprotective agent has been reported for treatment of PD. Herein, we present a novel organic-inorganic composite nanoparticle with brain targeting (lf-protocells) for co-delivery of levodopa and curcumin, and demonstrate its attractive use as a biocompatible platform for PD treatment. The nanoparticle system is comprised of a lactoferrin (lf) modified lipid bilayer (LB) containing curcumin as its outer membrane and mesoporous silica nanoparticles (MSNs) containing levodopa as its supporting inner core. Our studies illustrate that the lf-protocells have a spherical morphology, and can be used to co-load levodopa and curcumin efficiently; the combination of curcumin and levodopa alleviates the apoptosis of PD cells, decreases the expression of a-synuclein and increase the expression of tyrosine hydroxylase in SH-SY5Y cells as compared to single drug; the binary-drug loaded lf-protocells ameliorate oxidative stress and mitochondrial dysfunction as compared to combination of free drugs; lf-protocells improve significantly the distribution in brain compared with unmodified protocells; binary-drug loaded lf-protocells have better performance of motor function in mouse than unmodified protocells and combination of free drugs. In conclusion, binary-drug loaded lf-protocells show better therapeutic efficacy in both cell model and mouse model of PD than combination of free drugs and lower toxicity than bare MSNs. These results suggest that lf-protocells can be used as a promising drug delivery platform for targeted therapy against PD and other diseases of the central nervous system.
Subcutaneous Levodopa: A New Engine for the Vintage Molecule

Karolina Poplawska-Domaszewicz,Lucia Batzu,Cristian Falup-Pecurariu,K. Ray Chaudhuri

DOI: https://doi.org/10.1007/s40120-024-00635-4

2024-06-16

Neurology and Therapy

Abstract:The management of Parkinson's disease (PD) continues to evolve with advancements in non-oral levodopa-based therapies aiming to provide continuous drug delivery (CDD). Such therapies address the challenges posed by the emergence of motor fluctuations, dyskinesias, and non-motor fluctuations (NMF) associated with oral levodopa administration and contributing to define the advanced stage of PD. The key focus of this review is placed on subcutaneous foslevodopa/foscarbidopa (Foslevodopa/foscarbidopa) infusion, showcasing its recent clinical availability and efficacy in providing continuous levodopa delivery. While providing an overview of the other non-oral levodopa-based CDD systems, such as intrajejunal levodopa–carbidopa infusion and levodopa–entacapone–carbidopa infusion, we highlight the current promising evidence for Foslevodopa/foscarbidopa to improve, for example, "on time" without troublesome dyskinesia and reducing "off time" in people with advanced PD. Additionally, Foslevodopa/foscarbidopa demonstrates potential in managing early morning off periods, sleep quality and other motor and non-motor symptoms. Moreover, other non-oral CDD options such as ND0612 and DIZ102/DIZ101 are discussed, with focus on their pharmacokinetics/pharmacodynamics, efficacy, and safety profiles. While these advancements present new therapeutic avenues, long-term observational studies are warranted to elucidate their impact on existing PD therapies. Overall, this review provides insights into the evolving landscape of non-oral CDD therapies and offers a pragmatic approach for their integration into clinical practice.

clinical neurology
Preparation and Evaluation of Injectable Rasagiline Mesylate Dual-Controlled Drug Delivery System for the Treatment of Parkinson’s Disease

Ying Jiang,Xuemei Zhang,Hongjie Mu,Hongchen Hua,Dongyu Duan,Xiuju Yan,Yiyun Wang,Qingqing Meng,Xiaoyan Lu,Aiping Wang,Wanhui Liu,Youxin Li,Kaoxiang Sun

DOI: https://doi.org/10.1080/10717544.2017.1419514

IF: 6.819

2017-01-01

Drug Delivery

Abstract:Abstract A microsphere–gel in situ forming implant (MS–Gel ISFI) dual-controlled drug delivery system was applied to a high water-soluble small-molecule compound Rasagiline mesylate (RM) for effective treatment of Parkinson’s disease. This injectable complex depot system combined an in situ phase transition gel with high drug-loading and encapsulation efficiency RM–MS prepared by a modified emulsion-phase separation method and optimized by Box–Behnken design. It was evaluated for in vitro drug release, in vivo pharmacokinetics, and in vivo pharmacodynamics. We found that the RM-MS-Gel ISFI system showed no initial burst release and had a long period of in vitro drug release (60 days). An in vivo pharmacokinetic study indicated a significant reduction (p < .01) in the initial high plasma drug concentration of the RM–MS–Gel ISFI system compared to that of the single RM–MS and RM–in situ gel systems after intramuscular injection to rats. A pharmacodynamic study demonstrated a significant reduction (p < .05) in 6-hydroxydopamine-induced contralateral rotation behavior and an effective improvement (p < .05) in dopamine levels in the striatum of the lesioned side after 28 days in animals treated with the RM–MS–Gel ISFI compared with that of animals treated with saline. MS-embedded in situ phase transition gel is superior for use as a biodegradable and injectable sustained drug delivery system with a low initial burst and long period of drug release for highly hydrophilic small molecule drugs.
Lyotropic Liquid Crystalline Based Nasal Spray for Improved Parkinson's Treatment: Enhanced Superior Nasal Tract Deposition and Antioxidation Strategy

Xiao Xia,Ziqiao Zhong,Chunfu Wei,Guanlin Wang,Ziyu Zhao,Jingyu He,Zizhao Zhai,Yue Zhou,Wenhao Wang,Haihua Guo,Yuzhen Jin,Cenfeng Liu,Xiao Yue,Chuanbin Wu,Ying Huang,Xuejuan Zhang

DOI: https://doi.org/10.1002/adfm.202411426

IF: 19

2024-10-30

Advanced Functional Materials

Abstract:Based on the nose‐to‐brain drug delivery strategy, a lyotropic liquid crystalline‐based in situ gel nasal spray is constructed. The results demonstrate that the levodopa brain bioavailability is improved by 26 times. Besides, the co‐loaded epigallocatechin gallate further exerts an antioxidation strategy. As a result, the treatment efficiency of Parkinson's disease is significantly enhanced. The blood–brain barrier is one of the serious challenges in the treatment of Parkinson's disease (PD), which severely hinders the drug's brain bioavailability. In this study, a lyotropic liquid crystalline (LLC) based in situ gel nasal spray loaded with the first‐line drug Levodopa (LDA) for PD is developed to resolve this issue based on a nose‐to‐brain drug delivery approach. Specifically, the two key stages of LLC‐based in situ gel nasal spray, droplet deposition, and drug retention are tailored. By adjusting LLC's precursor solution's viscosity, the droplet deposition on the superior nasal tract can be increased by 18 times. Through nasal mucus‐triggered sol–gel transition, the LDA nasal cavity retention is prolonged by three times. The epigallocatechin gallate is incorporated into the LLC‐based in situ gel nasal spray to inhibit the autoxidation of LDA and alleviate the oxidative stress response in PD. The results show that the LLC‐based in situ gel nasal spray has a 26‐fold higher brain bioavailability of LDA compared to oral administration. The PD rats show a significant improvement in behavioral and cognitive disorders after administration. The LLC‐based in situ gel nasal spray is proved to work by reducing oxidative damage. This study is anticipated to offer a promising strategy for the clinical application of LDA.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Defying malaria: Fathoming severe Plasmodium vivax disease

Q. Bassat,P. Alonso

DOI: https://doi.org/10.1038/nm0111-48

Nature Network Boston

Abstract:
Computer-aided optimization of carbidopa/levodopa orally disintegrating tablets

Fucheng Qin,Congcong Wan,Yuanyuan Zhang

DOI: https://doi.org/10.1080/03639045.2024.2327475

IF: 3.727

2024-03-20

Drug Development and Industrial Pharmacy

Abstract:Objective This study aimed to optimize the formulation of carbidopa/levodopa orally disintegrating tablets (ODTs) in order to improve their disintegration performance, and facilitate easier medication intake for Parkinson's patients.

pharmacology & pharmacy,chemistry, medicinal
Poly(acrylic acid)/Poly(vinyl alcohol) Microarray Patches for Continuous Transdermal Delivery of Levodopa and Carbidopa: In Vitro and In Vivo Studies

Yaocun Li,Lalitkumar K. Vora,Jiawen Wang,Akmal Hidayat Bin Sabri,Andrew Graham,Helen O. McCarthy,Ryan F. Donnelly

DOI: https://doi.org/10.3390/pharmaceutics16050676

IF: 6.525

2024-05-18

Pharmaceutics

Abstract:Levodopa (LD) has been the most efficacious medication and the gold standard therapy for Parkinson's disease (PD) for decades. However, its long-term administration is usually associated with motor complications, which are believed to be the result of the fluctuating pharmacokinetics of LD following oral administration. Duodopa® is the current option to offer a continuous delivery of LD and its decarboxylase inhibitor carbidopa (CD); however, its administration involves invasive surgical procedures, which could potentially lead to lifelong complications, such as infection. Recently, dissolving microarray patches (MAPs) have come to the fore as an alternative that can bypass the oral administration route in a minimally invasive way. This work explored the potential of using dissolving MAPs to deliver LD and CD across the skin. An acidic polymer poly(acrylic acid) (PAA) was used in the MAP fabrication to prevent the potential oxidation of LD at neutral pH. The drug contents of LD and CD in the formulated dissolving MAPs were 1.82 ± 0.24 and 0.47 ± 0.04 mg/patch, respectively. The in vivo pharmacokinetic study using female Sprague–Dawley® rats (Envigo RMS Holding Corp, Bicester, UK) demonstrated a simultaneous delivery of LD and CD and comparable AUC values between the dissolving MAPs and the oral LD/CD suspension. The relative bioavailability for the dissolving MAPs was calculated to be approximately 37.22%. Accordingly, this work highlights the use of dissolving MAPs as a minimally invasive approach which could potentially bypass the gastrointestinal pathway and deliver both drugs continuously without surgery.

pharmacology & pharmacy
Development, optimization, and in vitro/in vivo evaluation of ranitidine hydrochloride resinate sustained release suspension

Meiping Han,Yi Du,Xiaowen Wu,Xin Zhang,Quanzhu Yang,Caleb Kesse Firempong,Hongfei Liu,Dongli Li

DOI: https://doi.org/10.4314/tjpr.v22i3.1

2023-04-19

Tropical Journal of Pharmaceutical Research

Abstract:Purpose: To prepare ranitidine hydrochloride (RH) sustained-release suspension aimed at improving its safety, effectiveness and convenience of administration. Methods: The RH resinate suspension was prepared using bath method, with a cation- exchange resin as carrier. To obtain an ideal sustained release effect, RH resinates were coated with Eudragit®RS100 using the surface coating method, followed by optimization through a single-factor experiment and response surface analysis. The optimized RH suspension was characterized using accelerated stability test. Moreover, it was pharmacokinetically evaluated in vivo. Results: The optimized RH resin microcapsules showed relative mean deviation between the predicted and measured release values that was 50; drug leakage < 0.5 %), with good redispersibility. Results from pharmacokinetics showed that values of Tmax for RH sustained-release suspension and RH common tablet were 4.00 and 2.5 h, respectively (p < 0.05), while the corresponding Cmax values were 2545.78 and 3245.97 ng/mL, respectively (p < 0.05). Results of analysis of AUC0-24 showed that they were equivalent in terms of AUC0-24 (p < 0.05) and bioavailability of 101.05%. Conclusion: The optimized ranitidine hydrochloride (RH) sustained-release suspension has been successfully prepared using ion-exchange resin as a carrier and Eudragit® RS100 as a coating material.

pharmacology & pharmacy
[Cross test with B-lymphocytes in transplantation immunology].

G. Laurentaci,G. Catalano,B. Favoino,V. Memeo,F. Selvaggi,A. Traficante

1980-05-31

Minerva Chirurgica

Abstract:Cross-matching procedure with B-lymphocytes may facilitate the detection of cytotoxic antibodies. This finding suggested a reliable use of the test in immune monitoring after kidney allograft from living donor. The possible enhancing role of B-lymphocyte antibodies was also discussed.
Formulation, Development, Evaluation and Solubility Enhancement of Lercanidipine Hydrochloride by Solid Dispersion Techniques

S. D. Mankar,Punit R. Rachh

DOI: https://doi.org/10.9734/jpri/2021/v33i53b33697

2021-12-07

Journal of Pharmaceutical Research International

Abstract:Background: Solid dispersions (SDs) are the dispersion of hydrophobic drugs in an inert hydrophilic carrier. SDs are prepared to improve the dissolution properties and bioavailability of slightly water-soluble drug molecules by dispersing them into an inert hydrophilic carrier. Aims and Objective: Evaluate the dissolution and solubility of Solid Dispersion of Lercanidipine Hydrochloride (LER). Materials and Methods: To study the effect of polymer, dissolution and solubility studies were carried out. Solid state characterizations of prepared solid dispersions were performed by differential scanning calorimetry (DSC).Drug- carrier interactions were studied by FT-IR spectroscopy, whereas X-ray diffraction of powder was done to demonstrate the crystal structure of the dispersions. Results: The prepared solid dispersion exhibited 94% drug release at 30 minutes which is higher than both LER pure and LER MKT. Better dissolution characteristic of solid dispersion was confirmed by 9.86 min MDT and 63.12% DE30 which is higher than that of LER MKT (13.64 MDT, 46.92 % DE30) Solid state characterization revealed that enhancement of dissolution is the result of conversion of crystalline form of LER to less crystalline and/or amorphous form. Conclusion: Solid dispersion of LER can successfully be prepared with the PEG6000 in the ratio of 1:6 using solvent evaporation technique. It is a successful and easy approach for the increase in onset of action of drug after administration and facilitates treatment of cardiovascular diseases.
Using a gestural interface toolkit for tactile input to a dynamic virtual space

T. Schiphorst,Robb Lovell,Norman Jaffe

DOI: https://doi.org/10.1145/506443.506581

2002-04-20

Abstract:In this paper, we describe the development of a gesture interface toolkit that has been applied to an application of tactile gesture recognition within an artificial life environment. The goal is to design a gestural semantics of caress, in which qualitative attributes of gesture are expressed as a function of tactility. A touch-sensitive tablet capable of detecting multiple simultaneous contacts was used to provide a source of tactile gestures (stroking, pressing, tapping, wrapping, spreading, pinching, nudging) which were then interpreted by the software as events to be sent to the active creature in the environment. Participants could observe the creature reactions within a three-dimensional immersive display system.

Correction: Programmable RNA microstructures for coordinated delivery of siRNAs.

Three-Dimensional Electrohydrodynamic Printing and Spinning of Flexible Composite Structures for Oral Multidrug Forms

Preparation and Quality Control of Levamlodipine Besylate Orally Disintegrating Tablets

Study on pramipexole dihydrochloride sustained-release tablets

Development and characterization of gastro-floating sustained-release capsule with improved bioavailability of levodopa

Novel liposomal formulations for protection and delivery of levodopa: Structure-properties correlation

Preparation and in vitro evaluation of a novel combined multiparticulate delayed-onset sustained-release formulation of diltiazem hydrochloride

Development of protocatechualdehyde proliposomes-based sustained-release pellets with improved bioavailability and desired pharmacokinetic behavior for angina chronotherapy

Testing HIV positive in pregnancy: A phenomenological study of women's experiences.

Non-invasive, continuous oral delivery of solid levodopa-carbidopa for management of Parkinson's disease

Co-loading of Levodopa and Curcumin Using Brain-targeted Protocells for Improving the Efficacy of Parkinson's Disease

Subcutaneous Levodopa: A New Engine for the Vintage Molecule

Preparation and Evaluation of Injectable Rasagiline Mesylate Dual-Controlled Drug Delivery System for the Treatment of Parkinson’s Disease

Lyotropic Liquid Crystalline Based Nasal Spray for Improved Parkinson's Treatment: Enhanced Superior Nasal Tract Deposition and Antioxidation Strategy

Defying malaria: Fathoming severe Plasmodium vivax disease

Computer-aided optimization of carbidopa/levodopa orally disintegrating tablets

Poly(acrylic acid)/Poly(vinyl alcohol) Microarray Patches for Continuous Transdermal Delivery of Levodopa and Carbidopa: In Vitro and In Vivo Studies

Development, optimization, and in vitro/in vivo evaluation of ranitidine hydrochloride resinate sustained release suspension

[Cross test with B-lymphocytes in transplantation immunology].

Formulation, Development, Evaluation and Solubility Enhancement of Lercanidipine Hydrochloride by Solid Dispersion Techniques

Using a gestural interface toolkit for tactile input to a dynamic virtual space